The anti-tumor effect of Bay 61–3606 and TRAIL <i>in vivo</i>.

(A) The mean tumor volumes are presented. After the average volumes of the tumors reached ~100 mm3, mice (n = 5/group) were injected intraperitoneally twice a week with TRAIL (10 mg/kg), Bay 61–3606 (50 mg/kg) or a combination of Bay 61–3606 (50 mg/kg) and TRAIL (10 mg/kg). Asterisks indicate significant differences compared with the control (* P <0.05, ** P <0.01, and *** P <0.001). (B) Protein extracts from tumor xenografts were analyzed for Mcl-1 expression by Western blotting after mice were sacrificed. (C) A suggested model for Bay 61–3606 for sensitizing TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.